Sökning: id:"swepub:oai:DiVA.org:liu-139292" >
Chronic urticaria i...
Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study
-
- Thomsen, S. F. (författare)
- Bispebjerg Hospital, Denmark; University of Copenhagen, Denmark
-
- Pritzier, E. C. (författare)
- Stavanger University Hospital, Norway
-
- Anderson, Chris (författare)
- Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Hudkliniken i Östergötland
-
visa fler...
-
- Vaugelade-Baust, N. (författare)
- Novartis Norge, Norway
-
- Dodge, R. (författare)
- Novartis Pharmaceut AS, Denmark
-
- Dahlborn, A. -K. (författare)
- Novartis Sweden AB, Sweden
-
- Vestergaard, C. (författare)
- Aarhus University Hospital, Denmark
-
visa färre...
-
(creator_code:org_t)
- 2017-04-03
- 2017
- Engelska.
-
Ingår i: Journal of the European Academy of Dermatology and Venereology. - : WILEY. - 0926-9959 .- 1468-3083. ; 31:6, s. 1048-1055
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundChronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. ObjectiveTo examine baseline data from Scandinavian AWARE patients. MethodsAWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (18 years) with a confirmed CU diagnosis (amp;gt;2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q(2)oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. ResultsOverall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m(2), respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score amp;lt;12) and had a spontaneous component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. ConclusionAdult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas